Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
FDA-approved: Intra-abdominal infections (complicated appendicitis and peritonitis), complicated skin and skin structure infections, bacterial meningitis, community-acquired pneumonia, nosocomial pneumonia, complicated urinary tract infections, septicemia, febrile neutropenia (in combination with other agents).,Off-label: Empiric therapy for presumed infections, endocarditis, osteomyelitis, septic arthritis, intra-abdominal infections due to resistant organisms.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
1 g IV every 8 hours infused over 15-30 minutes; dose range 0.5-2 g every 8 hours depending on infection severity
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
1.0–1.5 hours in healthy adults; prolonged to 4–6 hours in moderate renal impairment (Cr Cl 30–50 m L/min) and 8–12 hours in severe renal impairment (Cr Cl <10 m L/min).
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Meropenem is primarily metabolized by hydrolysis of the beta-lactam ring via renal dehydropeptidase-1 (DHP-1) located in the kidney, producing an inactive metabolite. It is not significantly metabolized by hepatic CYP450 enzymes.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal: ~70% unchanged via glomerular filtration and tubular secretion; hepatic metabolism: ~20% via hydrolysis of beta-lactam ring; fecal: <2%.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
~2% bound to serum proteins (primarily albumin).
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
0.23–0.35 L/kg, approximating extracellular fluid volume; indicates limited tissue penetration except in inflamed tissues.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
IV: 100% (only route); no oral bioavailability.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Cr Cl 26-50 m L/min: 1 g every 12 hours; Cr Cl 10-25 m L/min: 0.5 g every 12 hours; Cr Cl <10 m L/min: 0.5 g every 24 hours
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No adjustment required for hepatic impairment; pharmacokinetics unaffected by Child-Pugh class
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Infants ≥3 months and children: 20-40 mg/kg IV every 8 hours (max 2 g/dose); higher doses up to 60 mg/kg every 8 hours for meningitis
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Dose based on renal function (Cr Cl); no age-specific adjustments beyond renal considerations
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA black box warning for meropenem; however, carbapenems may cause serious hypersensitivity reactions and should be used with caution in patients with history of beta-lactam allergy.
None
Hypersensitivity reactions: Serious and occasionally fatal anaphylactic reactions, especially in patients with history of penicillin, cephalosporin, or other beta-lactam allergy.,Seizures: May cause CNS adverse effects including seizures, especially in patients with renal impairment, CNS disorders, or those receiving high doses.,Clostridioides difficile-associated diarrhea (CDAD): May range from mild diarrhea to fatal colitis; evaluate if diarrhea occurs.,Renal impairment: Dose adjustment required; may increase risk of seizures due to accumulation.,Bleeding: Reports of coagulation abnormalities, including prolonged prothrombin time and bleeding, particularly in malnourished or renal failure patients.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to meropenem or any component of the formulation.,Hypersensitivity to other carbapenems (e.g., imipenem, ertapenem).,History of anaphylactic reaction to penicillins or cephalosporins (relative contraindication).
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No known food interactions with meropenem. Sodium chloride content should be considered in patients on sodium-restricted diets.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Meropenem is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal harm, but no adequate and well-controlled studies exist in pregnant women. First trimester: No increased risk of major malformations reported in human data. Second and third trimesters: Use only if clearly needed; no known fetal toxicity at standard doses. However, caution is advised due to potential alteration of gut flora and risk of neonatal infection if used near delivery.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Meropenem is excreted into human breast milk in low concentrations (M/P ratio approximately 0.25). It is considered compatible with breastfeeding, but caution is advised in nursing infants with renal impairment, prematurity, or gastrointestinal pathology. Monitor infant for diarrhea, candidiasis, or allergic reactions.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No standard dose adjustments recommended for pregnancy alone. However, pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may reduce meropenem serum concentrations; consider monitoring therapeutic drug levels in severe infections and adjust dose if necessary, though specific dosing guidelines are not established. Use standard adult dosing (e.g., 1 g every 8 hours) as indicated for the infection.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Meropenem is a broad-spectrum carbapenem active against Gram-positive, Gram-negative, and anaerobic bacteria. In the Duplex Container formulation, meropenem is premixed with sodium chloride for IV administration; ensure the container is intact and the solution is clear before use. Dose adjustment required in renal impairment (Cr Cl <50 m L/min). Prolonged infusion (e.g., over 3 hours) may optimize pharmacokinetic/pharmacodynamic targets for resistant organisms. Contraindicated in patients with hypersensitivity to carbapenems or history of anaphylaxis to beta-lactams.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is given intravenously, usually every 8 hours, and must be administered by a healthcare professional.,Inform your doctor of any kidney problems, as the dose may need to be adjusted.,Report any signs of allergic reaction, such as rash, itching, swelling, or difficulty breathing, immediately.,Notify your healthcare provider if you have seizures or epilepsy, as meropenem may lower the seizure threshold.,Complete the full course of treatment even if you feel better.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"The serum concentration of Valproic acid can be decreased when it is combined with Meropenem."
"The serum concentration of Probenecid can be increased when it is combined with Meropenem."
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Meropenem."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is a Electrolyte that works by Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is: 1 g IV every 8 hours infused over 15-30 minutes; dose range 0.5-2 g every 8 hours depending on infection severity. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER is classified as Category A/B. Meropenem is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal harm, but no adequate and well-controlled studies exist in pregnant women. First tri. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.